High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model

Neurobiology of Aging

Volumn 31, Issue 9, 2010, Pages 1516-1531

  Julien, Carl ^a,b   Tremblay, Cyntia ^a,b   Phivilay, Alix ^a,b   Berthiaume, Line ^b   Émond, Vincent ^a,b   Julien, Pierre ^b   Calon, Frédéric ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Amyloid beta; Cofilin; Dietary fat; Docosahexaenoic acid; Drebrin; GFAP; LR11; PAK; Polyunsaturated fatty acid; Synaptophysin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; DETERGENT; DREBRIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; SYNTAXIN 3; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; FAT INTAKE; FRONTAL CORTEX; LIPID DIET; LOW FAT DIET; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARIETAL LOBE; PRIORITY JOURNAL; RISK FACTOR; TRANSGENIC MOUSE; WESTERN BLOTTING;

EID: 77954955083     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.08.022     Document Type: Article

References (83)

1. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
2. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
3. Bennett D.A., Schneider J.A., Wilson R.S., Bienias J.L., Arnold S.E. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 2004, 61:378-384.
4. Binder L.I., Guillozet-Bongaarts A.L., Garcia-Sierra F., Berry R.W. Tau, tangles, and Alzheimer's disease. Biochim. Biophys. Acta 2005, 1739:216-223.
5. Breckenridge W.C., Morgan I.G., Zanetta J.P., Vincendon G. Adult rat brain synaptic vesicles. II. Lipid composition. Biochim. Biophys. Acta 1973, 320:681-686.
6. Calon F. Nonpatentable drugs and the cost of our ignorance. CMAJ (Canadian Medical Association journal=journal de l'Association medicale canadienne) 2006, 174:483-484.
7. Calon F., Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:287-293.
8. Calon F., Lim G.P., Morihara T., Yang F., Ubeda O., Salem N., Frautschy S.A., Cole G.M. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 2005, 22:617-626.
9. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
10. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., Hyslop P.S.G., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat. Med. 1997, 3:67-72.
11. Corrigan F.M., Horrobin D.F., Skinner E.R., Besson J.A., Cooper M.B. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int. J. Biochem. Cell. Biol. 1998, 30:197-207.
12. Counts S.E., Nadeem M., Lad S.P., Wuu J., Mufson E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J. Neuropathol. Exp. Neurol. 2006, 65:592-601.
13. Dickson D.W., Crystal H.A., Mattiace L.A., Masur D.M., Blau A.D., Davies P., Yen S.H., Aronson M.K. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 1992, 13:179-189.
14. Dodson S.E., Gearing M., Lippa C.F., Montine T.J., Levey A.I., Lah J.J. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006, 65:866-872.
15. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J. Alzheimers Dis. 2008, 13:241-253.
16. Folch J., Lees M., Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226:497-509.
17. Forman M.S., Mufson E.J., Leurgans S., Pratico D., Joyce S., Leight S., Lee V.M., Trojanowski J.Q. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 2007, 68:757-763.
18. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 1998, 152:307-317.
19. Freund-Levi Y., Eriksdotter-Jönhagen M., Cederholm T., Basun H., Faxén-Irving G., Garlind A., Vedin I., Vessby B., Wahlund L.O., Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 2006, 63:1402-1408.
20. Galloway S., Pallebage-Gamarallage M.M., Takechi R., Jian L., Johnsen R.D., Dhaliwal S.S., Mamo J.C. Synergistic effects of high fat feeding and apolipoprotein E deletion on enterocytic amyloid-beta abundance. Lipids Health Dis. 2008, 7:15.
21. Giannakopoulos P., Herrmann F.R., Bussière T., Bouras C., Kövari E., Perl D.P., Morrison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
22. Green K.N., Martinez-Coria H., Khashwji H., Hall E.B., Yurko-Mauro K.A., Ellis L., LaFerla F.M. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 2007, 27:4385-4395.
23. Halagappa V.K.M., Guo Z., Pearson M., Matsuoka Y., Cutler R.G., LaFerla F.M., Mattson M.P. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2007, 26:212-220.
24. Harigaya Y., Shoji M., Shirao T., Hirai S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J. Neurosci. Res. 1996, 43:87-92.
25. Hatanpää K., Isaacs K.R., Shirao T., Brady D.R., Rapoport S.I. Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 1999, 58:637-643.
26. Hayashi K., Shirao T. Change in the shape of dendritic spines caused by overexpression of drebrin in cultured cortical neurons. J. Neurosci. 1999, 19:3918-3925.
27. Heredia L., Helguera P., de Olmos S., Kedikian G., Solá Vigo F., LaFerla F., Staufenbiel M., de Olmos J., Busciglio J., Cáceres A., Lorenzo A. Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J. Neurosci. 2006, 26:6533-6542.
28. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
29. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., Hyman B.T., Irizarry M.C. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931.
30. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103:5161-5166.
31. Jones C.R., Arai T., Rapoport S.I. Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem. Res. 1997, 22:663-670.
32. Julien C., Berthiaume L., Hadj-Tahar A., Rajput A.H., Bédard P.J., Paolo T.D., Julien P., Calon F. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem. Int. 2006, 48:404-414.
33. Julien C., Tremblay C., Bendjelloul F., Phivilay A., Coulombe M.A., Emond V., Calon F. Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology. J. Neurosci. Res. 2008, 86:2292-2302.
34. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
35. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
36. Klaiman G., Petzke T.L., Hammond J., Leblanc A.C. Targets of caspase-6 activity in human neurons and Alzheimer disease. Mol. Cell Proteomics 2008, 7:1541-1555.
37. Kumar-Singh S., Theuns J., Broeck B.V., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R., Broeckhoven C.V. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum. Mutat. 2006, 27:686-695.
38. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
39. Lepage G., Roy C.C. Direct transesterification of all classes of lipids in a one-step reaction. J. Lipid. Res. 1986, 27:114-120.
40. Li L., Cao D., Garber D.W., Kim H., Fukuchi K. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am. J. Pathol. 2003, 163:2155-2164.
41. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem N., Frautschy S.A., Cole G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25:3032-3040.
42. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
43. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20:5709-5714.
44. Luchsinger J.A., Mayeux R. Adiposity and Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:127-134.
45. Luchsinger J.A., Tang M., Shea S., Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch. Neurol. 2002, 59:1258-1263.
46. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., Serhan C.N., Bazan N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115:2774-2783.
47. Ma Q.L., Teter B., Ubeda O.J., Morihara T., Dhoot D., Nyby M.D., Tuck M.L., Frautschy S.A., Cole G.M. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J. Neurosci. 2007, 27:14299-14307.
48. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
49. McGowan E., Eriksen J., Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006, 22:281-289.
50. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Schneider J., Wilson R.S. Dietary fats and the risk of incident Alzheimer disease. Arch. Neurol. 2003, 60:194-200.
51. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., Aggarwal N., Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60:940-946.
52. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., Litchfield S., Smith A., Barnetson L., Smith A.D. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 1995, 6:21-31.
53. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
54. Nguyen T.V., Galvan V., Huang W., Banwait S., Tang H., Zhang J., Bredesen D.E. Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J. Neurochem. 2008, 104:1065-1080.
55. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging. 2003, 24:1063-1070.
56. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
57. Offe K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I., Lah J.J. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J. Neurosci. 2006, 26:1596-1603.
58. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lutjohann D., Hartmann T., Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 2006, 23:563-572.
59. Pamplona R., Dalfó E., Ayala V., Bellmunt M.J., Prat J., Ferrer I., Portero-Otín M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 2005, 280:21522-21530.
60. Panter S.S., McSwigan J.D., Sheppard J.R., Emory C.R., Frey W.H. Glial fibrillary acidic protein and Alzheimer's disease. Neurochem. Res. 1985, 10:1567-1576.
61. Parrott M.D., Greenwood C.E. Dietary influences on cognitive function with aging: from high-fat diets to healthful eating. Ann. N. Y. Acad. Sci. 2007, 1114:389-397.
62. Pasinetti G.M., Zhao Z., Qin W., Ho L., Shrishailam Y., Macgrogan D., Ressmann W., Humala N., Liu X., Romero C., Stetka B., Chen L., Ksiezak-Reding H., Wang J. Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. Interdiscipl. Top. Gerontol. 2007, 35:159-175.
63. Pawlosky R.J.J., Salem N. Recent advances in the supply of docosahexaenoate to the nervous system. Fatty Acids: From Neuronal Membrane to Physiological and Behavioral Function 2001, 115-123. Humana Press, Totowa, NJ. D. Mostofsky, S. Yehuda, N. Salem (Eds.).
64. Plourde M., Fortier M., Vandal M., Tremblay-Mercier J., Freemantle E., Bégin M., Pifferi F., Cunnane S.C. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:301-308.
65. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 1998, 23:81-88.
66. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., Zhao W., Thiyagarajan M., Macgrogan D., Rodgers J.T., Puigserver P., Sadoshima J., Deng H., Pedrini S., Gandy S., Sauve A.A., Pasinetti G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 2006, 281:21745-21754.
67. Rapoport S.I., Rao J.S., Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot. Essent. Fatty Acids. 2007, 77:251-261.
68. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7:321-331.
69. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K.L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L.A., Cuenco K.T., Green R.C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R.P., Inzelberg R., Hampe W., Bujo H., Song Y.Q., Andersen O.M., Willnow T.E., Graff-Radford N., Petersen R.C., Dickson D., Der S.D., Fraser P.E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L.A., St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39:168-177.
70. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., Tucker K.L., Kyle D.J., Wilson P.W.F., Wolf P.A. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 2006, 63:1545-1550.
71. Scherzer C.R., Offe K., Gearing M., Rees H., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I., Lah J.J. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 2004, 61:1200-1205.
72. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996, 2:864-870.
73. Sekino Y., Kojima N., Shirao T. Role of actin cytoskeleton in dendritic spine morphogenesis. Neurochem. Int. 2007, 51:92-104.
74. Shim K.S., Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci. Lett. 2002, 324:209-212.
75. Skinner E.R., Watt C., Besson J.A., Best P.V. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 1993, 116(Pt 3):717-725.
76. Söderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
77. Tan J., Town T., Crawford F., Mori T., DelleDonne A., Crescentini R., Obregon D., Flavell R.A., Mullan M.J. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 2002, 5:1288-1293.
78. Tremblay C., Pilote M., Phivilay A., Emond V., Bennett D.A., Calon F. Biochemical characterization of abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J. Alzheimers. Dis. 2007, 12:377-390.
79. Wirths, O., Breyhan, H., Marcello, A., Cotel, M.C., Brück, W., Bayer, T.A. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging, in press, published on-line on July 28, 2008; doi:10.1016/j.neurobiolaging.2008.06.011.
80. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
81. Wyss-Coray T., Lin C., Yan F., Yu G.Q., Rohde M., McConlogue L., Masliah E., Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001, 7:612-618.
82. Yao, J.K., Wengenack, T.M., Curran, G.L., Poduslo, J.F. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem. Res. in press, published on-line on March 29, 2008; doi:10.1007/s11064-008-9673-1.
83. Zhao L., Ma Q., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., Weisbart R.H., Teter B., Frautschy S.A., Cole G.M. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 2006, 9:234-242.